| Literature DB >> 30598237 |
Agnès Viguier1, Valérie Lauwers-Cances2, Pascal Cintas3, Véronique Manel4, Sylviane Peudenier5, Isabelle Desguerre6, Susana Quijano-Roy7, Catherine Vanhulle8, Mélanie Fradin9, Arnaud Isapof10, Michaël Jokic11, Michèle Mathieu-Dramard12, Klaus Dieterich13, Florence Petit14, Corinne Magdelaine15, Fabienne Giuliano16, Domitille Gras17, Damien Haye18, Mathilde Nizon19, Maryse Magen19, Eric Bieth20, Claude Cances21.
Abstract
Spinal muscular atrophy with respiratory distress type 1 (SMARD1) is a rare autosomal recessive neuromuscular disorder characterized by progressive motor and respiratory decline during the first year of life. Early and late-onset cases have recently been reported, although not meeting the established diagnostic criteria, these cases have been genotyped. We thus conducted a national multicenter observational retrospective study to determine the prognosis of children with SMARD1 according to their phenotype. We recorded all known French pediatric cases with mutations identified on the immunoglobulin μ-binding protein 2 gene and the presence of respiratory symptoms. Thirty centers provided 22 observations. A diaphragmatic palsy was diagnosed 1.5 months (p = 0.02) after first respiratory symptoms, and hypotonia preceded areflexia by 4 months (p = 0.02). Early onset of symptoms leading to specialist consultation before the age of 3 months was associated with a significantly worse prognosis (p < 0.01). Among the 6 patients who were still alive, all were tracheostomized. Only one case survived beyond 2 years without artificial ventilation. The remaining patients died at a median age of 7 months. Our results may help pediatricians to provide medical information to parents and improve the decision-making process of setting up life support.Entities:
Keywords: DSMA1; Heterogeneity; IGHMBP2; Multicenter; Prognosis; SMARD1
Mesh:
Substances:
Year: 2018 PMID: 30598237 DOI: 10.1016/j.nmd.2018.10.002
Source DB: PubMed Journal: Neuromuscul Disord ISSN: 0960-8966 Impact factor: 4.296